PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1193421
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1193421
The Lentiviral Vectors Market size was valued at USD 120.6 Million in 2021, expanding at a CAGR of 12.8% from 2023 to 2030.
Lentiviral vectors are utilized to introduce a foreign genetic element into another cell. These vectors are made from lentivirus, which has a lengthy incubation period and may infect both dividing and non-dividing cells.
Market Dynamics
The global lentiviral vectors market is anticipated to increase as a result of numerous manufacturers' research and development efforts for novel lentiviral gene treatments. For instance, pre-clinical evidence AVR-RD-03 for Pompe disease was presented by AVROBIO, Inc. in May 2020, a gene therapy business in the clinical stage. The study demonstrated the promise of lentiviral gene therapy for Pompe disease symptoms in the central nervous system and muscles (CNS).
Additionally, modern healthcare facilities and the rise in cancer incidence worldwide are the two main factors boosting the market under study. Globally, there were 1,92,92,789 new cancer cases in 2020, and 2,88,87,940 instances are expected by 2040, according to GLOBOCAN 2020. The increase in the incidence of cancer worldwide and the availability of sophisticated healthcare facilities are important factors in the market's expansion. Numerous Phase I, Phase II, Phase III, and Phase IV clinical trials involving viral vectors for the treatment of various cancers, including brain, skin, liver, colon, breast, and kidney, are scheduled to begin in 2021. These studies are being carried out in several academic institutions and biotechnology firms. For instance, the National Clinical Trial (NCT) Registry reports that as of March 2021, there were more than 90 active interventional clinical trials including gene therapy that were being conducted worldwide and involved various stages of research for cancer.
Segmentation Analysis:
The Global Lentiviral Vectors Market is segmented based on product type, indication, end user, and region.
Based on product type, the market is bifurcated into 1st-generation, 2nd-generation, and 3rd-generation. In 2021, the 1st-generation lentiviral vector category held a sizable market share for lentiviral vectors. Due to its usage in the treatment of a variety of ailments, the category is predicted to dominate the market for lentiviral vectors. The gag and pol genes, as well as several additional viral proteins, were all present in 1st-generation lentiviral vectors, which also included a sizable amount of the HIV genome.
Regional Analysis:
North America held the largest market share in 2021 and is expected to continue this pattern over the forecast period. Clinical research on rare diseases has taken centre stage in the United States due to regulatory support and patient engagement. The Orphan Drugs Act (the United States) offers considerable incentives that have prompted pharmaceutical and biotechnology companies to view the creation of medications for rare diseases as a potentially lucrative endeavour. Numerous companies in the region have been developing their facilities and making large capital investments. For instance, Merck KgaA and MilliporeSigma announced intentions to invest USD 110 million to open a second viral vector plant at their Carlsbad, California site in April 2020. The company's capacity to produce gene therapy was anticipated to increase by a factor of two with the planned expansion. The development of novel viral vectors has evolved dramatically, and many researchers are focusing on the therapeutic DNA replacement of harmful genes. Non-pathogenic, replication-defective, and human-friendly viral vectors are routinely utilised in current gene therapy clinical trials. Given the expected increase in viral vector research, these advances might help the market expand.
Recent Development:
In April 2021, Lentiviral vector manufacturing facilities are being opened by VIVEbiotech, S.L., a gene transfer technologies CDMO that develops and produces lentiviral vectors for the cell and gene therapy industries. The facility will be able to produce batches for early-stage research as well as GMP for clinical and upcoming commercial usage.
In November 2023, ElevateBio BaseCamp introduced the patented LentiPeakTM lentiviral vector platform. A technology-driven firm focused on enabling transformational cell and gene therapies have been made public. Regulatory-compliant therapeutically relevant vector yields have been produced with great volumetric productivity using the serum-free, suspension-based LentiPeak production platform. LentiPeak will provide a rapid and cost-effective transition for cell and gene therapies from the preclinical stage through clinical development and commercialization.
Key features of the study:
This proposed research study on the Lentiviral Vectors market provides market size (US$ Million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains an attractive investment proposition matrix for the Lentiviral Vectors market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Lentiviral Vectors market
The impact of COVID-19 on the Lentiviral Vectors market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight into the Lentiviral Vectors market post-COVID will also be covered.
To give the users of this report a comprehensive view of the Lentiviral Vectors market, we have also included a competitive landscape and key innovator analysis for the Lentiviral Vectors market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand the financial information and strategic initiatives of players operating in the Lentiviral Vectors market.
In addition, the report also unveils the important acquisitions & mergers, collaborations & joint ventures, new launches, research & development, and regional expansion of major participants involved in the market on global as well as regional levels.
The global Lentiviral Vectors market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL LENTIVIRAL VECTORS MARKET KEY PLAYERS
FinVector
Charles River Laboratories
FUJIFILM Holdings Corporation
Kaneka Eurogentec S.A.
Merck KGaA
uniQure NV
Oxford Biomedica
Johnson & Johnson Services, Inc.
AstraZeneca
Vibalogics
Danaher
Sanofi
GLOBAL LENTIVIRAL VECTORS MARKET, BY PRODUCT TYPE
1st-generation
2nd-generation
3rd-generation
GLOBAL LENTIVIRAL VECTORS MARKET, BY INDICATION
HIV
B-thalassemia
X-linked Adrenoleukodystrophy
Metachromatic Leukodystrophy
Wiskott-Aldrich Syndrome
GLOBAL LENTIVIRAL VECTORS MARKET, BY END USER
Hospitals
Clinics
Research Institutes
GLOBAL LENTIVIRAL VECTORS MARKET, BY REGION
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA